PrEP Truvada Oral denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for prep truvada oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied PrEP (Truvada) as Experimental

An "experimental or investigational" denial from Cigna means the plan is claiming the drug or its use lacks sufficient clinical evidence to be considered standard of care. For oral Truvada used as HIV pre-exposure prophylaxis (PrEP), this denial is almost always incorrect on its face: the FDA granted a specific PrEP indication, and the U.S. Preventive Services Task Force (USPSTF) has assigned PrEP a Grade A recommendation — the highest level. Major health authorities including the CDC publish clinical practice guidelines supporting its use. Cigna's own medical policies typically recognize FDA-approved indications as non-experimental; when a denial ignores this, it is a strong candidate for appeal.

## Why This Denial Is Appealable

Federal and state insurance law require that "experimental" denials be based on a genuine, current review of the medical evidence. A denial that ignores an FDA approval and a USPSTF Grade A recommendation is inconsistent with that standard and with the insurer's own stated criteria. The ACA's coverage mandate for USPSTF Grade A preventive services (for non-grandfathered plans) adds a separate, independent basis to contest this denial without cost-sharing.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair internal review. The denial notice must state the appeal deadline; preserve it carefully.
• External review: After exhausting internal appeals, you may request review by an independent IRO at no cost. The external-review window is generally within four months of the final internal denial. Expedited review (72-hour turnaround) is available when delay would seriously jeopardize your health.
• ACA preventive-services argument: For non-grandfathered plans, separately assert that PrEP is a mandated preventive service under the ACA based on the USPSTF Grade A recommendation; cost-sharing and coverage barriers for such services are subject to their own legal challenge.

## Concrete Appeal Process and Timeline

1. Pull Cigna's medical coverage policy for the specific experimental/investigational criteria being applied. 2. Collect the FDA approval documentation for the PrEP indication (publicly available from FDA.gov). 3. Have your prescriber write a medical-necessity and standard-of-care letter citing current guideline-body support. 4. Submit internal appeal with all materials. 5. If denied, file for external IRO review within the stated window.

## Documentation to Gather

• HIV-negative status: Recent lab results confirming your status at the time of prescribing.
• Prescriber letter: A letter from your provider explaining that oral Truvada for PrEP is FDA-approved for this indication and is consistent with USPSTF, CDC, and applicable infectious-disease society guidelines — without citing specific numbers, but naming the guideline organizations.
• Clinical risk documentation: Notes establishing PrEP candidacy per current guidelines.
• FDA label reference: A copy of the FDA-approved prescribing information confirming the PrEP indication.

## Criteria-Mapping Structure

For each "experimental" criterion Cigna states in the denial, map it directly to evidence:

| Cigna Experimental Criterion | Your Rebuttal Evidence | |---|---| | [Copy exact language from denial] | [FDA approval / guideline org citation / prescriber attestation] |

A precise point-by-point rebuttal — using Cigna's own policy language against the denial — is the most effective approach for experimental-use appeals.